Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab induction in unresectable stage III squamous cell lung carcinoma
NCT02428764Phase 2Withdrawn
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2015
- Primary completion
- Oct 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nimotuzumab in squamous cell carcinoma of the lung (SCCL), sponsored by Sun Yat-sen University. Planned start Apr 2015; status: withdrawn.
02
Drugs
nimotuzumab
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT02428764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02428764.